# Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma

> **NCT02632006** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Second Military Medical University** · enrollment: 40 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** PIK-PD-1 cells
- **BIOLOGICAL:** DC-PMAT

## Key facts

- **NCT ID:** NCT02632006
- **Lead sponsor:** Second Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-09
- **Primary completion:** 2017-03
- **Final completion:** 2017-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2016-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02632006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02632006, "Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02632006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*